We have successfully implemented the Windsor Framework requirements for human medicines packaging and labelling across all of our products. This achievement ensures that all Colonis UK human medicinal products placed on the UK market from 1^st January 2025 have clearly legible ‘UK Only’ text on their packaging. This is to show that they are for sale in the UK and not in EU countries.   

What does this mean for our customers?  

Any Colonis products placed on the UK market (QP and RPi certified) after 1^st January 2025 will have the ‘UK Only’ label.  

Existing stock, already QP certified and placed on the market before 1^st January 2025, will remain available for supply in the UK until its expiry date.  

Thanks to our swift implementation of the Windsor Framework, we will not face any stock outages during the transition, meaning you won’t notice any delays in receiving stock.  

Why is this important?   

We have proactively implemented the requirements of the Windsor Framework, demonstrating our commitment to compliance and quality as well as supporting the aims of the Medicines and Healthcare products Regulatory Agency (MHRA).  

At Colonis, we are dedicated to providing high-quality medicinal products to our patients. We understand the importance of maintaining a smooth and efficient supply chain and, by implementing the Windsor Framework requirements in good time, we are ensuring that you won’t face any negative impact caused by lack of compliant stock. 

Abbreviations: 

QP, Qualified Person. 
RPi, Responsible Person (import). 

GB-CPL-0-225
January 2025